Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
The successful human papillomavirus (HPV) and hepatitis B virus (HBV) subunit vaccines contain single viral proteins that represent 22% and 12%, respectively, of the total antigens encoded by these simple viruses. The herpes simplex virus 2 (HSV-2) genome is 20 and 50 times larger, respectively. Thus, single protein subunit vaccines represent only 1% of HSV-2’s total antigenic breadth. The concept of antigenic breadth offers a unifying explanation for why HSV-2 glycoprotein D subunit vaccines have repeatedly failed in human clinical trials, and why live HSV-2 vaccines that encode 99% of HSV-2’s antigens are more effective in side-by-side tests. We believe that live HSV-2 vaccines represent an unexplored opportunity to stop the genital herpes epidemic.
